Eutrepia is gaining share rapidly, generating cash, and supporting management's more-than-$1 billion 2027 revenue outlook.
| Quarter | Q2 FY26 |
|---|---|
| Call date | 2026-08-12 |
| Length | 41 minutes |
| EPS | $0.74 |
| EPS consensus | $0.70 |
| Revenue | $171.7M |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q4 FY25 · Q3 FY25
Read the full Q2 FY26 earnings call transcript
All LQDA earnings · Back to LQDA overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.